Status:
WITHDRAWN
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients
Lead Sponsor:
ModernaTX, Inc.
Conditions:
Cytomegalovirus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seroposi...
Eligibility Criteria
Inclusion
- Having a negative (that is, CMV-seronegative) or a positive (that is, CMV-seropositive) result using a blood IgG assay performed at the central laboratory or a previously documented seropositive result.
- Listed and anticipated to receive their first deceased donor or living donor liver transplant within 2 months to 12 months of enrollment.
- A person of nonchildbearing potential, as defined in the protocol.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, and agreement to continue adequate contraception or abstinence through 3 months following last study injection.
Exclusion
- Listed as "status 1A" for liver transplant.
- Hypersensitivity to acyclovir, ganciclovir, or valganciclovir.
- Previous receipt of a solid organ or hematopoietic transplant.
- Listed for or anticipated to receive an organ transplant other than liver, either simultaneously or sequentially.
- Receipt of prior investigational CMV vaccines or participation in another CMV therapeutic study that may interfere with study outcome measures as determined by the Investigator.
- Suspected or known allergic reaction to any component of any mRNA vaccine, including mRNA-1647, or its excipients.
- Human immunodeficiency virus (HIV) infection (based on documented testing performed during the transplant evaluation process and no clinical suspicion of HIV infection).
- Prior (ever) receipt of a stem cell transplant (peripheral blood stem cell, marrow, cord blood).
- Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
- Note: Other inclusion and exclusion criteria may apply.
Key Trial Info
Start Date :
February 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2027
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06133010
Start Date
February 8 2024
End Date
December 14 2027
Last Update
March 15 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.